Asthma control, monitoring, children, exhaled nitric oxide
Conditions
Interventions
Children will be randomly allocated to 1 of 3 treatment algorithms:
1. Control group: treatment according to national guidelines
2. FENO group: FENO guides treatment
3. Web group: an Internet program with monthly ACTs guides treatment.
Sponsors
Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Children 4-18 years old with allergic asthma, using inhaled corticosteroids for at least 3 months preceding the study; 2. Children and/or their parents should have access to the Internet at home; 3. Children should bij able to perform FENO measurements.
Exclusion criteria
Exclusion criteria: 1. Active smoking; 2. Chronic lung disease other than asthma; 3. Inabilily of parents or older children (>11 years) to read or understand Dutch.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the proportion of symptom free days (SFD) during the 4 weeks before the final visit (t =12 months). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are: 1. Daily and nocturnal symptoms, limitation of activities, use of rescue and controller medication as assessed with diary cards during the 4 weeks before visit t = 12 months; 2. Asthma related quality of life assessed with the PAQLQ; 3. Compliance with treatment during the 4 weeks before visit t=12 months, as assessed by diary cards and pharmacy data; 4. Airway hyperresponsiveness (PD20 methacholine); 5. FENO; 6. Spirometry (FEV1, FEF25%); 7. Exacerbations: unscheduled doctor visits related to asthma, systemic steroid courses, emergency room visits and hospital admissions all related to asthma; 8. ICS dose; 9. Patient utilities (EQ-5D); 10. Costs (CostQ). | — |
Contacts
Public ContactT.A.S. Bergen, van
Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology Dr. Molenwaterplein 60
Outcome results
None listed